company background image
V16 logo

Virbac DB:V16 Stock Report

Last Price

€346.00

Market Cap

€2.9b

7D

4.1%

1Y

19.3%

Updated

25 Mar, 2024

Data

Company Financials +

V16 Stock Overview

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East.

V16 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for V16 from our risk checks.

Virbac SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Virbac
Historical stock prices
Current Share Price€346.00
52 Week High€359.00
52 Week Low€237.50
Beta0.90
1 Month Change1.17%
3 Month Change-1.84%
1 Year Change19.31%
3 Year Change58.35%
5 Year Change140.61%
Change since IPO218.60%

Recent News & Updates

Recent updates

Shareholder Returns

V16DE PharmaceuticalsDE Market
7D4.1%3.0%1.3%
1Y19.3%-25.6%6.4%

Return vs Industry: V16 exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.

Return vs Market: V16 exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is V16's price volatile compared to industry and market?
V16 volatility
V16 Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: V16 has not had significant price volatility in the past 3 months.

Volatility Over Time: V16's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19685,459Sebastien Huronhttps://corporate.virbac.com

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.

Virbac SA Fundamentals Summary

How do Virbac's earnings and revenue compare to its market cap?
V16 fundamental statistics
Market cap€2.91b
Earnings (TTM)€121.30m
Revenue (TTM)€1.25b

24.0x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
V16 income statement (TTM)
Revenue€1.25b
Cost of Revenue€433.87m
Gross Profit€813.03m
Other Expenses€691.73m
Earnings€121.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 13, 2024

Earnings per share (EPS)14.49
Gross Margin65.20%
Net Profit Margin9.73%
Debt/Equity Ratio9.6%

How did V16 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

9%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.